GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Net Income From Continuing Operations

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Net Income From Continuing Operations : $-3.86 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. TC BioPharm (Holdings)'s net income from continuing operations for the three months ended in Mar. 2024 was $-4.22 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.86 Mil.

TC BioPharm (Holdings) Net Income From Continuing Operations Historical Data

The historical data trend for TC BioPharm (Holdings)'s Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Net Income From Continuing Operations Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-9.04 -8.91 -19.92 -1.60 -7.48

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.77 0.36 - -4.22

TC BioPharm (Holdings) Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Net Income From Continuing Operations
Comparable Companies
XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN XKRX:068270 XBRU:UCB RPRX INCY
Traded in Other Exchanges
T0U:Germany
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
Website
https://www.tcbiopharm.com
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD